Eli Lilly takes aim at illicit market for its experimental weight-loss drug
The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
